Research programme: PARP-inhibitors - 2X Oncology

Drug Profile

Research programme: PARP-inhibitors - 2X Oncology

Latest Information Update: 21 Feb 2017

Price : $50

At a glance

  • Originator Unknown
  • Developer 2X Oncology
  • Class Antineoplastics
  • Mechanism of Action Poly(ADP-ribose) polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Breast cancer

Most Recent Events

  • 31 Jan 2017 Early research in Breast cancer in USA
  • 31 Jan 2017 2X Oncology licenses PARP-inhibitor from an unknown company
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top